Yiyang Biopharmaceutical Co., Ltd.
GPTKB entity
Statements (58)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
Various smaller biotech firms
|
| gptkbp:awards |
gptkb:National_Quality_Award
Innovation Award |
| gptkbp:businessModel |
B2B
B2C |
| gptkbp:CEO |
gptkb:Zhang_Jian
|
| gptkbp:certifications |
gptkb:ISO_9001
GMP |
| gptkbp:clinicalTrials |
Completed
Ongoing |
| gptkbp:collaborations |
Local universities
Research institutions |
| gptkbp:community_engagement |
Scholarship programs
Health education programs Public health campaigns Volunteer_programs |
| gptkbp:employees |
Over 1,000
|
| gptkbp:exportMarkets |
gptkb:Asia
gptkb:Latin_America gptkb:North_America gptkb:Southeast_Asia Africa Europe |
| gptkbp:financialPerformance |
Publicly traded
|
| gptkbp:founded |
1997
|
| gptkbp:founder |
Li Wei
|
| gptkbp:future_plans |
Sustainability initiatives
Global expansion Market entry strategies New product launches Product diversification Increased R&D investment Partnership expansions Innovation leadership |
| gptkbp:headCoach |
1,500+
|
| gptkbp:headquarters |
gptkb:Yiyang,_Hunan,_China
|
| https://www.w3.org/2000/01/rdf-schema#label |
Yiyang Biopharmaceutical Co., Ltd.
|
| gptkbp:industry |
Pharmaceuticals
|
| gptkbp:investmentFocus |
Infrastructure development
R&D funding |
| gptkbp:market |
gptkb:China
Varies |
| gptkbp:partnerships |
International pharmaceutical companies
|
| gptkbp:products |
Biopharmaceuticals
Injectable drugs |
| gptkbp:regulatoryCompliance |
gptkb:CFDA
|
| gptkbp:research_focus |
Oncology
Autoimmune diseases Diabetes Cardiovascular diseases |
| gptkbp:revenue |
Varies
|
| gptkbp:social_responsibility |
Community health initiatives
Environmental sustainability programs |
| gptkbp:specialization |
Research and development
|
| gptkbp:stockExchange |
gptkb:Yiyang_Biopharmaceutical
|
| gptkbp:subsidiary |
gptkb:Yiyang_Pharmaceutical_Co.,_Ltd.
|
| gptkbp:website |
www.yiyangbio.com
|